Allianz Asset Management GmbH Lowers Stake in Natera, Inc. $NTRA

Key Points

• Allianz Asset Management GmbH reduced its stake in Natera, Inc. by 18.1% in Q2, owning 206,349 shares valued at approximately $34.86 million at the end of the quarter.
• Despite Allianz's reduction, other institutional investors, such as Price T Rowe Associates and UBS AM, have significantly increased their holdings, indicating ongoing confidence in Natera's prospects.
• Analysts have a consensus rating of "Moderate Buy" for Natera, with a price target averaging $196.81, reflecting positive growth expectations for the company.

Allianz Asset Management GmbH reduced its position in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 18.1% in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 206,349 shares of the medical research company's stock after selling 45,534 shares during the quarter. Allianz Asset Management GmbH owned 0.15% of Natera worth $34,861,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of NTRA. Price T Rowe Associates Inc. MD increased its stake in Natera by 56.3% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 10,537,743 shares of the medical research company's stock valued at $1,490,144,000 after purchasing an additional 3,795,315 shares in the last quarter. Nuveen LLC bought a new stake in Natera during the 1st quarter valued at about $113,375,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Natera by 140.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,253,790 shares of the medical research company's stock valued at $177,298,000 after purchasing an additional 732,156 shares in the last quarter. JPMorgan Chase & Co. increased its stake in Natera by 9.9% during the 1st quarter. JPMorgan Chase & Co. now owns 7,361,963 shares of the medical research company's stock valued at $1,041,055,000 after purchasing an additional 660,538 shares in the last quarter. Finally, Ninety One UK Ltd increased its stake in Natera by 149.1% during the 2nd quarter. Ninety One UK Ltd now owns 562,985 shares of the medical research company's stock valued at $95,111,000 after purchasing an additional 336,985 shares in the last quarter. 99.90% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, CFO Michael Burkes Brophy sold 2,491 shares of the business's stock in a transaction on Tuesday, September 30th. The shares were sold at an average price of $162.05, for a total value of $403,666.55. Following the sale, the chief financial officer owned 69,189 shares in the company, valued at approximately $11,212,077.45. The trade was a 3.48% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Steven Leonard Chapman sold 14,083 shares of the business's stock in a transaction on Wednesday, October 1st. The stock was sold at an average price of $160.00, for a total transaction of $2,253,280.00. Following the completion of the sale, the chief executive officer owned 154,072 shares in the company, valued at $24,651,520. This represents a 8.38% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 72,464 shares of company stock valued at $10,963,125 in the last three months. Corporate insiders own 5.63% of the company's stock.

Wall Street Analysts Forecast Growth

NTRA has been the subject of a number of analyst reports. Barclays restated an "overweight" rating and set a $210.00 price objective (up from $190.00) on shares of Natera in a research note on Friday, August 8th. Cowen reaffirmed a "buy" rating on shares of Natera in a report on Friday, August 8th. Piper Sandler reaffirmed an "overweight" rating and set a $220.00 price target (up previously from $210.00) on shares of Natera in a report on Monday, August 11th. Evercore ISI upgraded shares of Natera to a "strong-buy" rating and set a $170.00 target price on the stock in a research note on Monday, July 28th. Finally, Royal Bank Of Canada set a $268.00 target price on shares of Natera and gave the stock an "outperform" rating in a report on Tuesday, September 2nd. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Natera currently has a consensus rating of "Moderate Buy" and a consensus price target of $196.81.

Natera Stock Performance

NTRA stock opened at $181.69 on Friday. Natera, Inc. has a one year low of $117.27 and a one year high of $187.34. The company's fifty day moving average price is $168.19 and its 200-day moving average price is $158.46. The company has a market capitalization of $24.94 billion, a PE ratio of -95.13 and a beta of 1.74.

Natera (NASDAQ:NTRA - Get Free Report) last released its earnings results on Thursday, August 7th. The medical research company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.14). Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.The company had revenue of $546.60 million during the quarter, compared to analysts' expectations of $476.84 million. During the same period last year, the firm posted ($0.30) EPS. Natera's quarterly revenue was up 32.2% compared to the same quarter last year. Natera has set its FY 2025 guidance at EPS. On average, research analysts predict that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.